Darbari Deepika S, Minniti Caterina P, Rana Sohail, van den Anker John
Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC 20010, USA.
Am J Hematol. 2008 Mar;83(3):233-6. doi: 10.1002/ajh.21027.
Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine.
吗啡常用于治疗与镰状细胞病（SCD）相关的疼痛发作，但在许多患者中可能无法提供足够的镇痛效果。这篇简要综述聚焦于与SCD相关的生理变量中独特的疾病相关变化，这些变化会影响吗啡的药代动力学和药效学，并可能导致镇痛效果的差异。新出现的证据表明，涉及阿片类（UGT2B7、OPRM1和ABCB1基因）和非阿片类系统（COMT基因）的基因中的等位基因变异可改变吗啡的疗效。
